1. A kallikrein-like enzyme in plasma of patients with acute pancreatitis was further purified by successive hydroxyapatite/cellulose and Sepharose-4B column chromatography.
Introduction
Many reports have been made concerning the important role of the kallikrein-kinin system in acute pancreatitis. Worthington & Cuschieri (1976) reported that arginine esterolytic activity was significantly elevated in plasma of patients with acute pancreatitis and speculated that one of Correspondence: Naotika Toki, Department of Dermatology, Hiroshima University, School of Medicine, Kasumi 1-2-3, Hiroshima 734, Japan. the plasma estero lytic enzymes might be. a kallikrein originating from the pancreas. DIScovery of a kallikrein-like enzyme in the plasmã -macroglobulin fraction of patients with acute pancreatitis was reported (Sumi, Takasugi & Toki, 1978) and the authors succeeded in isolating the enzyme from~-macroglobulin fraction by SDS/Sephadex G-200 gel column chromatography (Takasugi, Toki & Sumi, 1980) . Some of the biochemical and biological properties of the enzymes were compared with those of human plasma kallikrein and it was strongly suggested that, in view of its molecular weight and ability to be absorbed on DEAE-cellulose, It might be human pancreatic kallikrein, which is different from human plasma kallikrein. In the present study an attempt was made to clarify whether or not this enzyme is pancretic kallikrein by using successive column chromatography for purification and double immunodiffusion for immunological characterization. Furthermore the interaction between purified pancreatic kallikrein and~-macroglobu1in was investigated.
Materials and methods

Materials
The following commercial preparations were used: D-Val-Leu-Arg p-nitroanilide hydrochloride (S-2266, Kabi Diagnostica Co. Ltd), Glu-Gly-Arg p-nitroanilide (S-2444, Daiichi Pure Chemical Co.), p-tosyl-L-arginine methyl ester (Sigma), , hydroxyapatite (Seikagaku Kogyo Co. Ltd), cellulose Mikrokristallin (Merck), Sepharose-4B (Pharmacia), aprotinin (Trasylol) (Bayer), soya bean trypsin inhibitor (Sigma), ethyl-p-(6-guanidinohexanoyloxy)-benzenemethane sulphonate (FOY) (Research Laboratories of Ono Pharmaceutical Co., Osaka) and p-tosyl-L-Iysine chloromethyl ketone (7-amino-l-chloro-3-L-tosylamidoheptan-2-one, TLCK) (Sigma).
Preparation of human plasma kallikrein and a-macroglobuttn
Human plasma kallikrein was obtained as described in a previous report (Toki & Yamura, 1979) . Human plasma kallikrein (1 mg) was found to possess 213 chromozyme units (defined below). Human urinary and pancreatic kallikrein were kindly supplied by Green Cross Co. Ltd, Osaka. The specific activity of human urinary and pancreatic kallikrein was 262 and 197 chromozyme units/mg of protein respectively, Human plasma Q2-macroglobulin was purified by the method as described previously (Toki, Ishihara & Yamura, 1977) . The concentration of protein in~-macroglobulin was 0·3 mg/ml and its specific activity was 15·5 units/mg. One unit was expressed as the amount of inhibitor required to inhibit completely 1·0 casein unit of trypsin, which was defined as the amount releasing 60 ug of acid-soluble tyrosine in 15 min on incubation at 37°C.
Assay ofenzyme and protein
In the present study the kallikrein-like and trypsin-like enzymes were determined by their amidolytic activity by using for the former chromogenic substrate S-2266 which is specific for glandular kallikrein and substrate S-2444 for the latter. One chromozyme unit was defined as the amount of enzyme required to hydrolyse 1 pmol of chromozyme/min under standard conditions. The final concentration of chromogenic substrate in the present study was 0·15 mmol/I for S-2266 and 0·3 mmol/I for S-2444 respectively. The esterolytic activity of trypsin-like enzyme was also determined by Hestrin's (1949) method. The inhibitory activities of various trypsin inhibitors on the trypsin-like enzyme were determined from the residual esterolytic and amidolytic activities of the enzyme after incubation with a mixture of enzyme and various amounts of inhibitors for predetermined periods at 37°C. Protein concentration was determined by the method of Lowry, Rosebrough, Farr & Randall (1951) by using bovine serum albumin (Merck) as the standard.
Electrophoretic technique
SOS/polyacrylamide-gel electrophoresis was carried out by the method of Weber & Osborn (1969) by using 7·5% (w/v) gel with 1% SOS and urea (8 mol/I). Electrophoresis was performed at 8 rnA/gel for 3 h. Gels were stained for 2 h with 2% (w/v) Coomassie brilliant blue and destained electrophoretically.
Estimation ofmolecular weight
The molecular weight of the purified kallikreinlike enzyme was estimated by the method of Andrews (1965) . Sephadex G-200 (2·5 ern x 50 ern) was equilibrated with Tris/HCI buffer (0·05 mol/I), pH 7·5, containing KCI (0·2 mol/I) and elution was performed at 4°C at a flow rate of about 15 ml/h.
Preparation ofantiserum
Purified kallikrein-like enzyme (2 mg) was dissolved in 1·0 ml of sodium chloride solution (150 mmol/l), mixed with an equal volume of complete Freund's adjuvant and injected into toe pads of a rabbit. After 4 weeks the rabbit received, as a booster dose, the same amount of enzyme injected subcutaneously into the back. After 2 weeks a blood sample was drawn and incubated at 37°C for 3 h and at 4°C for 18 h before serum separation by centrifugation at 2400 g.
Immunodiffusion
Immunodiffusion was carried out by the method of Ouchterlony (1958) at room temperature for 24 h. Agar gel (Behringwerke) was prepared at a concentration of 1% in veronal buffer (I = 0·05, pH 8·6) containing 0·05% sodium azide.
Results
Purification ofthe kallikrein-like enzyme
As described previously (Takasugi et al., 1980) , the kallikrein-like enzyme was isolated from~-macroglobulin fraction by SOS/ Sephadex G-200 gel chromatography and eluted in the adsorbed fraction by OEAE-cellulose column chromatography. In the present study the kallikrein-like enzyme was further purified by successive column chromatography on hydroxyapatite/cellulose and Sepharose-4B. ,
Step
1.
Hydroxyapatite/cellulose column chromatography
Hydroxyapatite/cellulose was prepared by mixing hydroxyapatite and cellulose Mikro-kristallin at equal volumes in phosphate buffer (0·01 moI/l) at pH 7·4. The kallikrein-like enzyme fractions (total volume 35 ml, total activity 75·3 chromozyme units) obtained from the DEAE-cellulose column were dialysed overnight against phosphate buffer (0·01 mol/l) at pH 7·4 at 4°C. The dialysed solution was chromatographed on a hydroxyapatite/cellulose column (2·0 em x 8·0 em) that had been equilibrated with phosphate buffer (0·01 mol/l) at pH 7·4. The kallikrein-like enzyme was eluted with a linear gradient formed from 100 ml of equilibration buffer and 100 ml of phosphate butTer (0·1 mol/l) at pH 7·4, at a flow rate of 30 ml/h (Fig. 1) . One main peak with kallikrein-like activity was eluted in fraction nos. 41-56 which were combined, concentrated to 5 ml by ultrafiltration and dialysed against phosphate buffer (0·05 mol/l) at pH 7·4.
Step 2. Sepharose-4B gelfiltration
The partially purified kallikrein-like enzyme obtained from step 1 (about 5 ml) was subjected to gel filtration on Sepharose-4B (2·0 em x 65 em) which had been equilibrated with phosphate buffer (0·05 mol/l) at pH 7·4. The column was eluted with the same buffer at a flow rate of 15 ml/h and fractions of 5 ml were collected. The protein was eluted as a single peak and the kallikrein-like enzyme fractions were pooled and concentrated to 0·1 vol. by ultrafiltration. The overall purification and yield of kallikrein-like enzyme are summarized in Table 1 . A final yield of o· 26 mg of purified preparation was obtained from 10 ml of the original plasma. The specific activity of the final product was 215 S-2266 chromozyme units/mg of protein.
Homogeneity
The final preparation of the kallikrein-like enzyme gave a single band in SDS/polyacrylamide-gel electrophoresis (Fig. 2) .
Estimation ofmolecular weight
The approximate molecular weight of the kallikrein-like enzyme was estimated by gel filtration on a Sephadex G-200 column by the method of Andrews (1965) . The molecular weight of the kallikrein-like enzyme was found to be 31 000 on the basis of a linear relationship between the elution volumes of marker proteins and the logarithms of their molecular weights.
Immunological identification
The identity of the kallikrein-like enzyme was investigated by a double immunodiffusion method by using human plasma, urinary or pancreatic kallikrein. As shown in Fig. 3 , rabbit antiserum against the kallikrein-like enzyme formed a single immunoprecipitin line with See the text for details of column chromatography. To measure the kallikrein or trypsin activity in each fraction 0·05 ml of each fraction was added to test tubes containing 0·1 ml of chromozyme S-2266 (1·5 mmol/I) or S-2444 (3 mmol/l) and 0·85 ml of Tris/HCl buffer (0·05 mol/I, pH 8·2). After incubation at 37°C for 10 min, 0·1 ml of 50% (v/v) acetic acid was added and A 40 5 was read against blanks. 
Preparation ofthe trypsin-like enzyme
As described previously (Takasugi et al., 1980) some proteolytic enzymes other than pancreatic kallikrein were isolated from lIz-macroglobulin by SDS/Sephadex G-200 column chromatography. DEAE-cellulose column chromatography also showed that the kallikrein-like enzyme fractions were contaminated with a trypsin-like enzyme because they possessed caseinolytic activity. In the present study, to examine the effect of the trypsin-like enzyme on interaction between lIzmacroglobulin and pancreatic kallikrein, the trypsin-like enzyme was partially purified. As shown in Fig. I protein was obtained from 10 ml of the original plasma. Although its purity is not yet confirmed, its molecular weight was about 26 000 by the gel filtration method. Furthermore this enzyme was confirmed to be trypsin from the inhibitory spectra of some trypsin inhibitors for the esterolytic and amidolytic activities of this enzyme (Table   2) .
Interaction between purified a-macroglobulin and purified pancreatic kallikrein
The interaction between lIz-macroglobulin and pancreatic kallikrein was investigated by mixing 5 ml of purified lIz-macroglobulin (containing I· 5 mg of protein, 23· 3 units) with 2 ml of purified pancreatic kallikrein (0·087 mg of protein, 18·7 S-2266 units) which was incubated for 1 h at 25°C, and then chromatographed on Sephadex G-200 (2·5 ern x 50 ern), As shown in Fig. 4(a) , the amidolytic activity of pancreatic kallikrein was eluted in fractions different from lIzmacroglobulin fractions.
Effect of trypsin on interaction between u 2 -macroglobulin and pancreatic kallikrein
To examine the effect of trypsin on the complex-formation between lIz-macroglobulin and pancreatic kallikrein 1· 5 ml of trypsin (0·043 mg of protein, 4·8 S-2444 chromozyme units) was added to test tubes containing 5 ml of purified lIz-macroglobulin and 2 ml of purified TABLE 2. Inhibitory spectrum of trypsin-like enzyme KIV, Kallikrein inhibitory unit. Values express the amount of inhibitor that is required to completely inhibit 0·1 mg of enzyme. To measure the inhibitory effect of various inhibitors on p-tosyl-Larginine methyl ester esterolytic or 5-2444 amidolytic activity of trypsin-like enzyme. 0·5 or 0·1 ml of enzyme solution was mixed with various amounts of inhibitor respectively. After the incubation for 15 min at 37°C 0·5 ml of p-tosyl-L-arginine methyl ester (20 mmol/I) or 0·1 ml of 5-2444 (3 mmol/I) was added and the mixture incubated for I h or 10 min respectively.
Substrate Inhibitor
Soya bean Aprotinin trypsin inhibitor (KJU) (ug)
Ethyl-p-(6-guanidinohexanoyloxy)-benzenemethanesulphonate
amount of pancreatic kallikrein that combined with~-macroglobulin was calculated from the S-2266 amidolytic activity in the~ macroglobulin fractions. The amount of pancreatic kallikrein bound to 2 .umol of~ macroglobulin was increased in proportion to the increase in the amount of trypsin and reached a plateau with a concentration of 2 .umoL The amount of pancreatic kallikrein bound to~ macroglobulin at the plateau was 4 .umoL This result shows that the binding capacity of -macroglobulin for trypsin and pancreatic kallikrein approaches saturation at 1 and 2 mol/mol of~-macroglobulin respectively. pancreatic kallikrein. After incubation for 1 h at 25°C, the reaction mixture was chromatographed on Sephadex G-200 (2·5 em x 50 ern), As shown in Fig. 4(b) , purified pancreatic kallikrein together with trypsin was eluted iñ -macroglobulin fractions. This result shows that 2·8 ,umol of pancreatic kallikrein can be combined with 2 ,umol of~-macroglobulin in the presence of 1·6 ,umol of trypsin. The stoicheiometry of this interaction was investigated on addition of various concentrations of trypsin to test tubes containing 2 .umol of a 2-macroglobulin and 10 ,umol of pancreatic kallikrein. After incubation for 1 h at 25°C, 8 ml of the reaction mixture was chromatographed on a Sephadex G-200 column (2·5 em x 50 em), The
Effect of preincubation of~-macroglobulin/ trypsin mixture on complex-jormation between ai-macrogiobulin and pancreatic kallikrein
To elucidate further the complexing mechanism between a 2-macroglobulin and pancreatic kallikrein the effect of preincubation of~ macroglobulin/trypsin mixture on complex-formation between~-macroglobulin and pancreatic kallikrein was examined. Trypsin (2 .umol) was added to 2 ,umol of~-macroglobulin. After incubation of the~-macroglobulin/trypsin mixture at 25°C for various time intervals, 4 .umol of pancreatic kallikrein was added and incubated at 25°C for 1 h. Then 8 ml of the reaction mixture was chromatographed on a Sephadex G-200 column (2·5 cm x 50 ern), As shown in Fig. 5 , the binding capacity of~-macroglobulin for pancreatic kallikrein was rapidly diminished by the preincubation.
Discussion
It has been reported that the release of a kallikrein-like enzyme into blood plays an impor- tant role in acute pancreatitis, but there are still many problems regarding its nature and origin. It is of particular importance to know whether the kallikrein-like enzyme in plasma from patients originates from the pancreas or from plasma kallikreinogen. During a series of studies on acute pancreatitis, the authors first succeeded in purifying this enzyme from plasma from patients. The purified material appeared homogeneous on SDS/ polyacrylamide-gel electrophoresis and its molecular weight was determined as 31 000 by gel filtration on a Sephadex G-200 column. In 1971 Tsutsumi reported that the molecular weight of purified human plasma kallikrein was 110 000. Moriya, Pierce & Webster (1963) also reported that the molecular weights of human urinary and pancreatic kallikreins were 40 500 and 31 200 respectively. When compared with their results, it seems likely that the purified kallikrein-like enzyme is pancreatic kallikrein, which is different from plasma kallikrein. OleMoiOi, Spragg, Halbert & Austen (1977) reported that urinary kallikrein was distinct from plasma kallikrein because anti-plasma kallikrein failed to react in immunodiffusion with purified urinary kallikrein. They also indicated that anti-pancreatic kallikrein reacted with purified urinary kallikrein and therefore surmised that the pancreatic kallikrein might be antigenically related to urinary kallikrein, but not to plasma kallikrein. In the present study, in an effort to confirm whether or not the kallikrein-like enzyme is a pancreatic kallikrein, its immunological characterization was investigated by an immunodiffusion method. When rabbit antiserum was applied to this purified enzyme a single immunoprecipitin line was formed with purified "0 E ". urinary and pancreatic kallikrein, but not with purified plasma kallikrein (Fig. 3) . These results are consistent with those of Ole-MoiOi et at. (1977) and provide confirmation that the kallikrein-like enzyme in the blood of patients with acute pancreatitis is pancreatic kallikrein.
Many reports on the interaction between plasma proteinases and proteinase inhibitors have been presented, but the interaction between lIz-macroglobulin and kallikrein in acute pancreatitis has been less understood. Harpel (1970) reported that human plasma kallikrein could combine with lIz-macroglobulin. Dyce, Wong, Adham, Mehl & Haverback (1967) and McConnell (1972) also indicated that plasma kallikrein released in acute pancreatitis could combine with lIz-macroglobulin. As confirmed in previous reports (Sumi et al., 1978; Takasugi et al., 1980) and in the present study almost all of the pancreatic kallikrein, which was released from the pancreas into blood, also combined with lIz-macroglobulin in plasma from patients. Conversely, Vahtera & Hamberg (1976) reported that pancreatic or urinary kallikrein could not combine with lIz-macroglobulin. If the findings of Vahtera & Hamberg (1976) are correct, how should we interpret the phenomenon of pancreatic kallikrein being combined with lIzmacroglobulin observed in the present study ? Vahtera & Hamberg (1976) also reported that, if pancreatic or urinary kallikrein could combine with lIz-macroglobulin, the complex-formation might be due to contamination with another proteinase in the kallikrein preparation. In an effort to resolve this question and clarify further the relationship between proteinase and lIzmacroglobulin in acute pancreatitis the interaction between purified lIz-macroglobulin and purified pancreatic kallikrein from plasma from patients was investigated. As shown in Fig. 4(a) , the purified pancreatic kallikrein could not combine with lIz-macroglobulin. Conversely, as suggested by Vahtera & Hamberg (1976) , the addition of trypsin to the lIz-macroglobulin and pancreatic kallikrein mixture prepared from plasma of a patient with acute pancreatitis gave rise to the formation of a complex between lIz-macroglobulin and pancreatic kallikrein (Fig.  4b) . These results indicate that the presence of trypsin is required for complex-formation between a 2 -macro globulin and pancreatic kallikrein.
In an effort to elucidate the importance of trypsin in the complexing mechanism between lIzmacroglobulin and pancreatic kallikrein the stoicheiometry of this interaction was investigated. The binding capacity of lIz-macroglobulin for trypsin approached saturation at a molar ratio of 1 : 1. In 1966 Ganrot found that the maximum molar binding capacity of~ macroglobulin for trypsin was 1·3-1· 7 mol. The lower trypsin-binding capacity in this study may be due to the different trypsin preparations used. There is another possibility that the complex-formation of~-macroglobulin and trypsin may be affected by the simultaneous complex-formation between~-macroglobulin and pancreatic kallikrein. The most important and interesting problem is why pancreatic kallikrein can combine with a 2 -macroglobulin in a 2 : 1 molar ratio in the presence of trypsin, despite the failure of complex-formation in the absence of trypsin. It has been found by many workers (Barrett & Starkey, 1973; Harpel, 1973; Roberts, Riesen & Hall, 1974 ) that alteration in the structure of~-macroglobulin (that is, peptide bond cleavage of the subunit chain in~ macroglobulin by the proteinase) is necessary for such complex-formation. The complexing mechanism of a 2 -macroglobulin for trypsin in this study is well understood from these studies. Although the number of enzyme-combining sites of~-macrog1obulin is still debatable (Barrett & Starkey, 1973) , it is difficult to confirm a molar ratio of 1: 2 for complex-formation of~ macroglobulin and pancreatic kallikrein from the stoicheiometry in the present study.
Conversely, in 1975 Ohlsson proposed that the molecular size and type of the enzyme first bound may perhaps decide the conformational change induced in~-macroglobulin in such a way as to permit or to inhibit the binding reaction of a second enzyme molecule. We consider that the binding of pancreatic kallikrein to~ macroglobulin in the presence of trypsin may also be due to a conformational change of~ macroglobulin induced after alteration of the subunit chain structure in~-macroglobulin by trypsin, which may bring about the exposure of the two binding sites for pancreatic kallikrein on the surface of one molecule of~-macroglobulin. We also speculate that the binding site of pancreatic kallikrein for~-macroglobulin is different from its active site because~ macroglobulin-bound pancreatic kallikrein itself possesses esterolytic and kinin-forming activities (Sumi et al., 1978) and that a weak bond, such as a hydrogen or hydrophobic bond, may be formed between~-macroglobulin and pancreatic kallikrein since pancreatic kallikrein can be separated from~-macroglobulin by SDS/Sephadex G-200 column chromatography (Takasugi et aI., 1980) . It is of particular interest that after preincubation at 25°C for more than 5 min~-macroglobulin/ trypsin mixture does not bind pancreatic kallikrein (Fig. 5) . This result suggests that the secondary molecular conformational change in~-macroglobulin for the complex-formation between~-macroglobulin and pancreatic kallikrein may be a temporary and reversible phenomenon.
